BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma

Graham J. Mann; Gulietta M. Pupo; Anna Campain; Candace D. Carter; Sarah‐Jane Schramm; Svetlana Pianova; Sebastien K. Gerega; Chitra De Silva; Kenneth Lai; James S. Wilmott; Maria Synnott; Peter Hersey; Richard Kefford; John F. Thompson; Jean Yang; Richard A Scolyer

doi:10.1038/jid.2012.283

Related publications

Article2021

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Richard A Scolyer, Victoria Atkinson, David Gyorki, Duncan Lambie, Sandra O’Toole, Robyn P.M. Saw, Benhur Amanuel, Christopher Angel, Alison Button‐Sloan, Matteo S. Carlino, Sydney Ch’ng, Andrew J. Colebatch, Dariush Daneshvar, Inês Pires da Silva, Tamara Dawson, Peter M. Ferguson, Erwin Foster‐Smith, Stephen B. Fox, Anthony J. Gill, Ruta Gupta, Michael A. Henderson, Angela Hong, Julie R. Howle, Louise Jackett, Craig James, C. Soon Lee, Alistair Lochhead, Daphne Loh, Grant A. McArthur, Catriona McLean, Alexander M. Menzies, Omgo E. Nieweg, Blake O’Brien, Thomas E. Pennington, Alison J. Potter, Saurabh Prakash, Robert V. Rawson, Rebecca L. Read, Michael Rtshiladze, Kerwin F. Shannon, B. Mark Smithers, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson, Paul Tucker, Alexander H. R. Varey, Ricardo E. Vilain, Benjamin A. Wood, Georgina V. Long

Article2014

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

Matteo S. Carlino, Lauren E. Haydu, Hojabr Kakavand, Alexander M. Menzies, Anne Hamilton, Bing Yu, C C Ng, Wendy A. Cooper, John F. Thompson, Richard Kefford, Sandra O’Toole, Richard A Scolyer, Georgina V. Long

Article2014

Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy

Gautier Stoll, David Enot, Bernhard Mlecnik, Jérôme Galon, Laurence Zitvogel, Guido Guido Kroemer

Article2017

Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients

Thomas R. Crookes, Richard A Scolyer, Serigne Lo, Martin Drummond, Andrew J. Spillane

Article2016

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

Jason Madore, Dario Strbenac, Ricardo E. Vilain, Alexander M. Menzies, Jean Yang, John F. Thompson, Georgina V. Long, Graham J. Mann, Richard A Scolyer, James S. Wilmott